Physician profile
Alan J Spanel
NPI 1023508892
$2,666.67
in general payments reported to CMS, 2019-2025
30 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.60 · 2022: $439 · 2023: $764 · 2024: $747 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.00 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $475.77 | 2022-2025 | Airsupra, Farxiga, Xigduo |
| Abbvie INC. | $372.62 | 2022-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $354.83 | 2021-2025 | |
| Novo Nordisk INC | $242.75 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $148.49 | 2021-2023 | Nucala, Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $134.07 | 2024-2025 | Zenpep |
| Amgen INC. | $127.38 | 2022-2025 | Evenity, Prolia, Otezla |
| Janssen Pharmaceuticals, INC | $70.31 | 2022 | |
| Lilly USA, LLC | $68.57 | 2021-2025 | Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $60.11 | 2025 | |
| Astellas Pharma US INC | $58.55 | 2023-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $58.00 | 2021-2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $49.97 | 2022-2024 | |
| Xeris Pharmaceuticals, INC. | $47.23 | 2024-2025 | Gvoke Hypopen |
| Biohaven Pharmaceutical Holding Company LTD. | $46.87 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $40.46 | 2025 | Rexulti |
| Abbott Laboratories | $39.38 | 2024-2025 | Freestyle Libre 3, Eterna |
| Phathom Pharmaceuticals, INC. | $35.31 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.73 | 2023-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.14 | 2021-2022 | |
| Forte Bio-Pharma LLC | $21.03 | 2024 | Prolate, Nalocet |
| Kyowa Kirin, INC. | $20.42 | 2023 | Crysvita |
| Axsome Therapeutics, INC. | $19.77 | 2022 | |
| Corcept Therapeutics | $19.70 | 2024 | Korlym |
| Celgene Corporation | $18.90 | 2022 | |
| Mallinckrodt Hospital Products INC. | $18.86 | 2025 | Acthar |
| Arbor Pharmaceuticals, INC. | $16.92 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.20 | 2025 | Rexulti |
| Radius Health, INC. | $13.06 | 2023 | Tymlos |
| Merck Sharp & Dohme LLC | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Spanel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.